TCF21: a critical transcription factor in health and cancer

Molecular Therapy - Oncolytics

Ding

et al. 2021

Self Cite

Gastric cancer (GC) is one of the most prevalent malignant tumor types and the third leading cause of cancer-related death worldwide. Its morbidity and mortality are very high due to a lack of understanding about its pathogenesis and the slow development of novel therapeutic strategies. Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs with a length of more than 200 nt. They play crucial roles in a wide spectrum of physiological and pathological processes by regulating the expression of genes involved in proliferation, differentiation, apoptosis, cell cycle, invasion, metastasis, DNA damage, and carcinogenesis. The aberrant expression of lncRNAs has been found in various cancer types. A growing amount of evidence demonstrates that lncRNAs are involved in many aspects of GC pathogenesis, including its occurrence, metastasis, and recurrence, indicating their potential role as novel biomarkers in the diagnosis, prognosis, and therapeutic targets of GC. This review systematically summarizes the biogenesis, biological properties, and functions of lncRNAs and highlights their critical role and clinical significance in GC. This information may contribute to the development of better diagnostics and treatments for GC.

Section: Roles Of Lncrnas In Gcmentioning

confidence: 99%

Long non-coding RNAs: Biogenesis, functions, and clinical significance in gastric cancer

Molecular Therapy - Oncolytics

Ding

et al. 2021

Self Cite

“…Therefore, we need valuable novel biomarkers as prognostic predictors for cancer patients to effectively increase the prognosis and precise therapy effects of cancer patients. Fortunately, some open bioinformatics databases have been established by biomedical researchers, such as Oncomine [36], CCLE [25], cBioPortal [29], and some potential novel biomarkers were identi ed as valuable prognostic predictors and therapeutic targets [37][38][39].…”

Section: Discussionmentioning

confidence: 99%

Systematic Analyses of the Expression, Function, and Prognostic Value of CCNBs in Breast Caner

Yu-qi

Wang

et al. 2021

Preprint

Background Cyclin B (CCNB) family plays key roles in the cell cycle, cell division and proliferation. Three members of CCNB family have been identified, including CCNB1, CCNB2 and CCNB3. Many studies have explored the roles of CCNBs in the tumorigenesis and pathogenesis of different types of cancer. However, the expression level, function, and prognostic value of CCNBs in breast caner (BC) are still unclear.Methods We explored the specific alterations of CCNBs in BC and predicted their prognostic value for BC patients. Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier plotter, cBioPortal, STRING, Database for Annotation,Visualization and Integrated Discovery (DAVID) databases were used for above analyses.Results We found that CCNB1 amd CCNB2 were significantly overexpressed in BC compared with normal samples, but not CCNB3. Survival analysis showed that upregulated CCNB1 and CCNB2 expression levels were associated with poor prognosis of BC patients, while high CCNB3 expression was related to good prognosis for BC patients. Furthermore, gene oncology (GO) enrichment analysis was performed to reveal the functions of CCNBs and the interacted genes related to CCNBs. In addition, hsa-miR-139-5p and has-miR-944 were identified to be potentially involved in the regulation of CCNB1.Conclusion Our study suggests that CCNB1, CCNB2 are potential targets of precise therapy for BC patients and that CCNB3 is a novel biomarker for the good prognosis of BC patients.

“…Understanding the mechanisms of miRNAs in signaling pathway regulation may facilitate the development of new therapeutic strategies against GC drug resistance. The PI3K/AKT signaling pathway is involved in the regulation of various cellular functions during cancer progression, such as proliferation, apoptosis, and metastasis (118,119). This pathway also confers drug resistance to various types of cancer, including GC (120).…”

Section: Mirnas Regulate the Drug Resistance Of Gc By Targeting Signaling Pathwaysmentioning

confidence: 99%

“…The PI3K/AKT signaling pathway is involved in the regulation of various cellular functions during cancer progression, such as proliferation, apoptosis, and metastasis ( 118 , 119 ). This pathway also confers drug resistance to various types of cancer, including GC ( 120 ).…”

Section: Implication Of Mirnas In Gc Drug Resistancementioning

confidence: 99%

Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer

et al. 2021

Front. Oncol.

Self Cite

Gastric cancer (GC) is one of the most common malignant tumors of digestive systems worldwide, with high recurrence and mortality. Chemotherapy is still the standard treatment option for GC and can effectively improve the survival and life quality of GC patients. However, with the emergence of drug resistance, the clinical application of chemotherapeutic agents has been seriously restricted in GC patients. Although the mechanisms of drug resistance have been broadly investigated, they are still largely unknown. MicroRNAs (miRNAs) are a large group of small non-coding RNAs (ncRNAs) widely involved in the occurrence and progression of many cancer types, including GC. An increasing amount of evidence suggests that miRNAs may play crucial roles in the development of drug resistance by regulating some drug resistance-related proteins as well as gene expression. Some also exhibit great potential as novel biomarkers for predicting drug response to chemotherapy and therapeutic targets for GC patients. In this review, we systematically summarize recent advances in miRNAs and focus on their molecular mechanisms in the development of drug resistance in GC progression. We also highlight the potential of drug resistance-related miRNAs as biomarkers and therapeutic targets for GC patients.